Interventional oncology: A snapshot of expanding practice

Azzam Khankan

doi:10.1055/s-0041-1728963

The Arab Journal of Interventional Radiology, Table of Contents

CC BY-NC-ND 4.0 · The Arab Journal of Interventional Radiology 2017; 01(01): 15-19
DOI: 10.1055/s-0041-1728963

Review Article

Interventional oncology: A snapshot of expanding practice

Azzam Khankan

Department of Medical Imaging, King Abdulaziz Medical City, P. O. Box 9515, Jeddah 21423, Saudi Arabia

› Author Affiliations

Abstract

PDF (411 kb)

PDF Download

Keywords:

Chemosaturation - immunoembolization - oncolytic virotherapy

References

References
1 Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ. Personalized oncology in interventional radiology. J Vasc Interv Radiol 2013;24:1083-92.
2 Kuruppu D, Tanabe KK. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther 2005;4:524-31.
3 Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-70.
4 Sze DY, Reid TR, Rose SC. Oncolytic virotherapy. J Vasc Interv Radiol 2013;24:1115-22.
5 Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy: Approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005;32:537-48.
6 Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol Ther 2006;13:938-46.
7 Mahoney DJ, Stojdl DF. Molecular pathways: Multimodal cancer-killing mechanisms employed by oncolytic vesiculoviruses. Clin Cancer Res 2013;19:758-63.
8 Pandha HS. Science in focus – Oncolytic viruses: New multifunctional immunotherapeutics. Clin Oncol (R Coll Radiol) 2016;28:615-8.
9 Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, et al. Locoregional intravascular viral therapy of cancer: Precision guidance for Paris's arrow? Gene Ther 2010;17:949-60.
10 Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, de Kruijf M, et al. The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011;37:618-32.
11 Yamamoto A, Sato T. Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am 2008;17:935-55, xii.
12 Canning C, O'Brien M, Hegarty J, O'Farrelly C. Liver immunity and tumour surveillance. Immunol Lett 2006;107:83-8.
13 Malter M, Friedrich E, Süss R. Liver as a tumor cell killing organ: Kupffer cells and natural killers. Cancer Res 1986;46:3055-60.
14 Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer 1994;73:2259-67.
15 Sullivan K. Immunoembolization for melanoma. 1st ed. New York: Cambridge University Press; 2008.
16 Kanai T, Monden M, Sakon M, Gotoh M, Umeshita K, Hasuike Y, et al. New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemother Pharmacol 1994;33 Suppl 1:S48-54.
17 Yoshida T, Sakon M, Umeshita K, Kanai T, Miyamoto A, Takeda T, et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: A clinicopathologic study. J Clin Gastroenterol 2001;32:59-65.
18 Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res 2004;24:3295-301.
19 Kenjo A, Sato T, Marubashi S, Saito T, Tsuchiya T, Kimura T, et al. Role of intratumoral infiltrating macrophages after transarterial immunoembolization for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2016;23:298-304.
20 Yuen MF, Ooi CG, Hui CK, Wong WM, Wong BC, Chan AO, et al. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 2003;97:2776-82.
21 Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2008;26:5436-42.
22 Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, et al. High-dose immunoembolization: Survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009;252:290-8.
23 Alexander HR Jr., Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 2000;5:416-24.
24 Jones A, Alexander HR Jr. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies. Surg Oncol Clin N Am 2008;17:857-76, x.
25 Vogel A, Gupta S, Zeile M, von Haken R, Brüning R, Lotz G, et al. Chemosaturation percutaneous hepatic perfusion: A systematic review. Adv Ther 2017;33:2122-38.
26 Alexander HR Jr., Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010;16:132-41.
27 Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol 2016;39:801-14.
28 Ku Y, Iwasaki T, Tominaga M, Fukumoto T, Takahashi T, Kido M, et al. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg 2004;239:53-60.
29 Uzgare RP, Sheets TP, Johnston DS. Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion. Anticancer Res 2013;33:1989-2000.
30 Ravikumar TS, Pizzorno G, Bodden W, Marsh J, Strair R, Pollack J, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994;12:2723-36.
31 Marinelli A, Vahrmeijer AL, van de Velde CJ. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res 1998;147:83-94.
32 Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: A phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000;82:1539-46.
33 de Vries MR, Borel Rinkes IH, van de Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: Experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 1998;147:107-19.
34 van Iersel LB, de Leede EM, Vahrmeijer AL, Tijl FG, den Hartigh J, Kuppen PJ, et al. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. Eur J Surg Oncol 2014;40:1557-63.
35 van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: Outcome and prognostic factors in 154 patients. Ann Oncol 2008;19:1127-34.
36 Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005;23:3465-74.
37 Deneve JL, Choi J, Gonzalez RJ, Conley AP, Stewart S, Han D, et al. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Intervent Radiol 2012;35:1480-7.
38 Lillemoe HA, Alexander HR. Current status of percutaneous hepatic perfusion as regional treatment for patients with unresectable hepatic metastases: A review. Am Oncol Hematol Rev 2014;15-23.